Glatect (glatiramer acetate for injection) is indicated for people with RRMS and individuals who have experienced a single demyelinating event and have lesions typical to multiple sclerosis of the brain.
“Multiple sclerosis disease-modifying drugs have revolutionized how we treat patients suffering from this disease, thus improving their quality of life,” said Jean-François Lemieux, vice-president and general manager of Pendopharm. “The launch of Glatect, a subsequent version of the original glatiramer acetate, provides a therapeutically equivalent alternative for Canadian patients living with multiple sclerosis.”
Canada has the highest rate of MS in the world, according to the MS Society. There are an estimated 100,000 Canadians living with the disease. MS is a chronic disease of the central nervous system that is characterized by inflammation and neurodegeneration.
Glatect is a synthetic protein made up of a combination of four amino acids that chemically resemble a component of myelin (the insulating material that protects nerves and helps them work properly).
Glatect induces the production of immune cells that are less damaging to myelin.
Before Glatect is initiated, people at risk of developing CDMS must have brain lesions on MRI and other possible diagnoses must be ruled out, according to MS Society of Canada.
Glatect is currently being evaluated by the Canadian Agency of Drugs and Technologies in Health (Common Drug Review). The agency will provide a recommendation for provincial public plan coverage for all Canadian provinces except Quebec.